Nature Medicine Review Maps the Expanding Landscape of GLP-1 Medicines
A comprehensive review by D.J. Drucker in Nature Medicine outlines GLP-1 medicines expanding beyond diabetes and obesity into cardiovascular disease, neurodegenerative disorders, substance use, metabolic liver disease, arthritis, type 1 diabetes, and inflammatory bowel disease. New multi-agonist molecules with optimized pharmacokinetics are producing greater weight loss.